Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 0.00% is 100% above its 5-year average of -165.33%, near the high end of its 5-year range (-3380.06%–0.00%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
-327.52%
NET PROFIT MARGIN AVG 5Y
-165.33%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+100.00%
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Spruce Biosciences, Inc.
Market Cap
$119.17M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-327.52%
5Y Avg
-165.33%
Market Cap
$119.15M
Net Profit Margin
-586.74%
TTM Avg
-215.13%
3Y Avg
-125.58%
5Y Avg
-83.72%
Market Cap
$118.12M
Net Profit Margin
-52.59%
TTM Avg
-29.17%
3Y Avg
-18.36%
5Y Avg
-9.63%
Market Cap
$119.78M
Net Profit Margin
-7723.97%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$120.60M
Net Profit Margin
-2258.89%
TTM Avg
-4695.34%
3Y Avg
-8719.58%
5Y Avg
-5863.11%
Market Cap
$121.23M
Net Profit Margin
-490.71%
TTM Avg
-538.75%
3Y Avg
-569.71%
5Y Avg
-1398.02%
Market Cap
$121.25M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$114.84M
Net Profit Margin
-959.76%
TTM Avg
-1140.14%
3Y Avg
-4837.22%
5Y Avg
-4160.74%
Market Cap
$114.24M
Net Profit Margin
-270.22%
TTM Avg
-342.92%
3Y Avg
-204.73%
5Y Avg
-136.49%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spruce Biosciences, Inc. (SPRB) | $119.17M | 0.00% | 0.00% | -327.52% | -165.33% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $119.15M | -586.74% | -215.13% | -125.58% | -83.72% |
| BGM Group Ltd. (BGM)vs › | $118.12M | -52.59% | -29.17% | -18.36% | -9.63% |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $119.78M | -7723.97% | 0.00% | 0.00% | 0.00% |
| Cibus, Inc. (CBUS)vs › | $120.60M | -2258.89% | -4695.34% | -8719.58% | -5863.11% |
| Seer, Inc. (SEER)vs › | $121.23M | -490.71% | -538.75% | -569.71% | -1398.02% |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.84M | -959.76% | -1140.14% | -4837.22% | -4160.74% |
| Coya Therapeutics, Inc. (COYA)vs › | $114.24M | -270.22% | -342.92% | -204.73% | -136.49% |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $124.26M | -548.64% | -1117.24% | -934.06% | -622.71% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | -3380.06% |
| 2024-09-30 | -1440.37% |
| 2024-06-30 | -570.25% |
| 2024-03-31 | -580.67% |
| 2023-12-31 | -344.65% |
| 2023-09-30 | -402.02% |
| 2023-06-30 | -592.33% |
| 2023-03-31 | -651.27% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
